EXTENZE Counterfeit Alert
By Dana Bushell
Biotab Nutraceuticals, Inc. (“Biotab”) is conducting a voluntary recall of two lots of EXTENZE nutritional supplement tablets. Some packages bearing lot numbers 0709241 and 0509075 are counterfeit products containing undeclared drug ingredients that can pose a serious risk to health. Biotab learned about the problem after being notified by the Food and Drug Administration (FDA) that two lots of counterfeit product purporting to be EXTENZE contained undeclared drug ingredients. More specifically, lot 0709241 contained tadalafil and sildenafil, and lot 0509075 contained tadalafil and sibutramine. All three drugs have been found to have adverse effects in those people taking prescription medication (nitrates) for treatment of blood pressure, diabetes, high cholesterol and heart disease. The counterfeit Extenze product is not manufactured, distributed or packaged by Biotab, but is falsely marked with the same lot numbers used by Biotab for its genuine product. Consumers in possession of product from the lots in question only should return any unused product to its immediate supplier for a direct refund. Biotab is committed to protecting the market place and its customers from counterfeit and adulterated product purporting to be authentic Extenze. Biotab will continue to cooperate with the FDA in order to ensure that all customers can rely on only finding genuine Extenze on the shelves of retailers. This recall is being conducted with the knowledge and gratitude of the U.S. Food and Drug Administration.
SOURCE: FDA via Anthony Roberts
COMMENTS